Opyl Limited

OPL

AU0000070856

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. Other stock markets 07:10:53 31/05/2024 BST			5-day change	1st Jan Change
0.022 ^AUD	+15.79%		+22.22%	-21.43%

04-29	Opyl Expands TrialKey Coverage; Shares Up 38%	MT
04-23	Opyl to Divest Opin Business	MT

Shareroot Limited Announces Cessation of Gary Steinepreis as Director, Effective from 12 January 2016

January 11, 2016 at 10:56 pm

ShareRoot Limited announced the cessation of Gary Steinepreis as director, effective from 12 January 2016.

Latest news about Opyl Limited

Opyl Expands TrialKey Coverage; Shares Up 38%	04-29	MT
Opyl to Divest Opin Business	04-23	MT
Opyl Receives Offer for Patient Recruitment Business	03-22	MT
Trial Screen Pty Ltd entered into a non-binding offer to acquire Opin business from Opyl Limited.	03-21	CI
Opyl Requests Trading Halt After Receiving Offer For Opin Business	03-20	MT
Opyl Chair Stepping Down in End-April	03-15	MT
Opyl Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-28	CI
Opyl Raises Nearly AU$900,000 from Rights Issue Shortfall Placement	02-09	MT
Opyl Grows Cash Receipts for Fiscal Q2	01-31	MT
Opyl Receives Commitments for Potential Shortfall	01-02	MT
Opyl Appoints Interim CEO	11-24	MT
Opyl Limited Appoints Saurabh Jain as Interim Chief Executive Officer	11-23	CI
Opyl Secures R&D Tax Rebate for Fiscal Year 2023	22/09/23	MT
Opyl Limited Announces Appointment of Antanas Guoga as Director, Effective from September 4, 2023	05/09/23	CI
Opyl Limited Announces Board Update	04/09/23	CI
Opyl Limited Reports Earnings Results for the Full Year Ended June 30, 2023	30/08/23	CI
Opyl Limited Launches TrialKey MVP	24/08/23	CI
Opyl Limited Announces Senior Leadership Changes	05/07/23	CI
Opyl Limited Announces Resignation of Michelle Gallaher as CEO	05/07/23	CI
Opyl Limited Appoints Dr. Hugo Stephenson as Board Advisor	02/05/23	CI
Opyl Completes Issuance of Shortfall Shares	04/04/23	MT
Opyl Limited Reports Earnings Results for the Half Year Ended December 31, 2022	26/02/23	CI
Opyl Limited Provides Earnings Guidance for the Fiscal Second Half of 2023	26/02/23	CI
Opyl Limited Announces Resignation of Julian Chick as Non-Executive Director	13/02/23	CI
Opyl Extends Rights Issue Closing Date	18/01/23	MT

Opyl Limited is an Australia-based artificial intelligence (AI) company. The Company leverages data and technology to transform the landscape of clinical trials and medical research. It is a digital health company, specialized in leveraging artificial intelligence technologies to elevate clinical trial design and forecast outcomes, empowering clinical researchers, biopharmaceutical corporations, and medical investors to enhance trial design, drug development, and market delivery. Its Social Media Insights solution captures and analyses online public conversations from people living with a medical condition, healthcare professionals, carers, and researchers. Its TrialKey platform provides users access to tailored, actionable steps to address critical trial challenges, improving the likelihood of success. The Company is specialized in applying AI and predictive analytics to social media to accelerate therapy adoption and market development in the healthcare industry.

Sector

Advanced Medical Equipment & Technology

Calendar

26/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Medical Software & Technology Services

	1st Jan change	Capi.
OPYL LIMITED	-21.43%	2.47M
VEEVA SYSTEMS INC.	-9.49%	28.16B
PRO MEDICUS LIMITED	+25.35%	8.33B
SECTRA AB	+33.25%	4.39B
EVOLENT HEALTH, INC.	-35.85%	2.43B
VERADIGM INC.	-9.44%	1.6B
OMNICELL, INC.	-13.39%	1.5B
LUNIT INC.	-32.84%	1.15B
SIMULATIONS PLUS, INC.	+7.80%	964M
B-SOFT CO.,LTD.	-37.56%	872M